IMPORTANCE Hypertriglyceridemia is the most frequent and limiting adverse effect of bexarotene therapy in cutaneous T-cell lymphoma (CTCL). Despite standard prophylactic measures, there is a wide variability in the severity of this complication, which could be associated with both genetic and environmental factors.
B exarotene, a synthetic retinoid and member of a subclass of retinoids called rexinoids, 1 was approved by the US Food and Drug Administration for the treatment of cutaneous T-cell lymphoma (CTCL) in 1999 and licensed in 2002 in Europe for the treatment of patients with advanced CTCL (stages IIB-IVB) refractory to at least 1 systemic treatment. Bexarotene has also been shown to be an effective and safe treatment for refractory early-stage CTCL (stages I-IIA). [1] [2] [3] [4] Dyslipidemia, mainly hypertriglyceridemia, and central hypothyroidism are the most common adverse effects of bexarotene. These effects are dose-related and reversible when drug treatment is discontinued. [5] [6] [7] This bexarotene-induced hypertriglyceridemia may be severe, and triglyceride levels of 991.15 mg/dL or greater (reference threshold, <160 mg/dL; to convert to millimoles per liter, multiply by 0.0113) can increase the risk of pancreatitis. 8 Guidelines recommend the use of prophylactic hypolipemic therapy from 1 week before beginning bexarotene treatment to maintain triglyceride levels less than 486.73 mg/dL in the general population and less than 309.73 mg/dL in patients with known cardiovascular disease. 1 It is recommended to start that treatment with a fibrate, usually fenofibrate, and simultaneously or later add a statin or ω-3 fatty acids if there is poor control of the dyslipemia.
1, 7, 9 Despite these prophylactic measures and strict lifestyle control, hypertriglyceridemia often cannot be avoided, and it is the principal cause of bexarotene therapy discontinuation. Risk factors for development of severe hypertriglyceridemia after bexarotene treatment have not been well defined. Environmental and genetic factors are both known to alter plasma triglyceride levels in the general population. 10 Triglyceride levels vary widely among and within individuals during bexarotene treatment. Thus, it would be of interest to identify genetic factors associated with the risk of developing severe hypertriglyceridemia during bexarotene therapy. In the general population, genes that code for apolipoprotein A5 (ApoA5), ApoC3, and ApoE are consistently directly associated with triglyceride concentrations. The minor allele of the APOA5 c.-1131T>C and c.56G>C single-nucleotide polymorphism, the APOC3 c.*40C>G polymorphism, and the APOE c.388T>C and c.526C>T polymorphisms are associated with higher triglyceride levels and also with risk for coronary artery disease, metabolic syndrome, and stroke. [11] [12] [13] [14] [15] The aim of this study was to analyze the association of these genetic polymorphisms of APOA5 (OMIM 606368), APOC3 (OMIM 107720), and APOE (OMIM 107741) with the severity of bexarotene-associated hypertriglyceridemia in patients with CTCL.
Methods
This retrospective, observational, noninterventionist, multicenter case series study was conducted in 12 Spanish university hospital dermatology departments from September 17, 2014 
Study Design and Data Collection
Patients eligible for inclusion were 18 years or older, had a confirmed diagnosis of CTCL, and had been treated for at least 3 months with bexarotene. To prevent selection bias, the investigator at each center obtained the list of living patients with CTCL and ordered them in reverse order of date of diagnosis, starting from the patient with the most recent diagnosis. Patients with severe renal or hepatic failure or who were being treated with drugs with a known hypertriglyceridemic adverse effect were excluded. Participants were interviewed to collect information on demographic characteristics, cardiovascular risk factors, and lifestyle habits. The following clinical findings were recorded: age, sex, weight, height, and body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared), smoking and alcohol consumption, diabetes, hypertension, previous dyslipidemia, physical exercise and dietary habits, histologic subtype, initial CTCL stage at diagnosis and stage at the beginning of bexarotene treatment, duration of bexarotene treatment, and response to the drug. For the evaluation of clinical response to bexarotene, all participating centers uniformly used the standard end points proposed by Olsen et al. 17 A saliva sample was collected during the medical visit for genetic study. Baseline analytic data, including renal and liver function, lipid profile, complete blood cell count, and thyroid hormone levels at 1 and 3 months after initiation of bexarotene treatment, were collected retrospectively. All pharmacologic treatment of these patients was provided as part of usual clinical practice. They also had received prophylactic hypolipidemic therapy from 1 week before the beginning of bexarotene treatment and 50 μg/d of levothyroxine sodium from the beginning of treatment, both continuing throughout bexarotene treatment. The investigator at each center collected the clinical and analytic data and thereafter provided those to a contract research organization specifically designed for the study. All data were encrypted and rendered anonymous so that the information collected in the centralized database could not identify the patients in the study. The entire procedure was strictly accomplished with the requirements of confidentiality pursuant to Spain's Organic Law 15/1999 on Protection of Personal Data.
Genetic Studies
Gene variant analysis was performed in the clinical laboratory of Bellvitge University Hospital. Saliva samples were collected, preserved, and transported in saliva-collection tubes (Oragene; DNA Genotek). DNA was extracted from saliva in an automated system (Maxwell16, model MX3031; Promega Corporation). All samples were codified and anonymized, and only the investigators responsible for the laboratory had access to them. We studied the presence of the minor allele vs homozygosis for the major allele for the following gene variants: c.-1131T>C (rs662799, APOA5); c.56G>C (rs3135506, APOA5); c.*40C>G (rs5128, APOC3); c.388T>C (rs429358, APOE*E4); c.526C>T (rs7412, APOE*E2). All were genotyped using allelespecific TaqMan probes (Life Technologies) in a real-time polymerase chain reaction system (iQ5; BioRad).
Statistical Analysis
All statistical analyses were performed using SPSS, version 19 statistical software (SPSS Inc). Deviations from HardyWeinberg equilibrium were assessed using the χ 2 test. Categorical and ordinal variables are presented as frequencies and percentages; means and SDs are used for continuous variables. The qualitative variables were analyzed using the χ 2 or
Fisher exact test and the quantitative variables using the paired, 2-tailed t test. To analyze the lipid profile data, the maximal lipid value for the individual patient during follow-up was registered. Continuous variables that were not normally distributed were log transformed to achieve normal distribution before fitting statistical models. To analyze which variables were associated with maximal triglyceride concentrations during bexarotene therapy, we used a stepwise multiple linear regression model with the variable log-maximal triglyceride level as the dependent variable and log-baseline triglyceride level, age, sex, BMI, and presence of minor alleles of each polymorphism as risk factors. Statistical significance was set at 2-sided P < .05.
Results
One hundred twenty-five patients met the inclusion criteria. Nine were subsequently excluded because they had missing analytic triglyceride level data. Therefore, 116 patients constituted the study group. /L, multiply by 1.0.) There were no statistically significant differences in glucose, liver profile, or hematocrit levels.
Genetic Studies
Genetic polymorphism frequencies and baseline characteristics are described in Table 2 . The genotype distribution was in Hardy-Weinberg equilibrium. By dividing number of minor alleles by number of total alleles and multiplying the quotient by 100, we obtained similar allelic frequencies of the minor allele in each gene, ranging from APOA5 c.-1131T>C as the most prevalent (9.5%) to the APOA5 c.56G>C as the least prevalent (6.9%). These frequencies did not deviate from previous data of the general white population, according to the Exome Aggregation Consortium database, version 1.0. 19 We observed a significant difference in genotype frequency between men and women in the APOA5 c. We observed a significant association between the initial triglyceride levels and their maximum increase during bexarotene treatment. For that, we performed an explanatory regression model of the log-maximal triglyceride, which showed that the only significant statistic variable was log-baseline triglyceride, accounting for 25% of the total variability (regression coefficient, 0.76 [95% CI, 0.51-1.01]; R 2 = 0.253; P < .001).
The higher the baseline triglyceride concentration, the higher the maximal triglyceride concentration reached during bexarotene treatment.
Discussion
Cutaneous T-cell lymphoma is a rare disease with a small prevalence. Bexarotene is an effective systemic therapy for patients with advanced or refractory CTCL, but hypertriglyceridemia, which was recorded in 82.7% of our study patients, used to be a limiting adverse effect. In this study, we aimed to evaluate the influence of several APO gene polymorphisms in the severity of hypertriglyceridemia induced by bexarotene therapy in patients with CTCL. The purpose of screening was to identify ideal patient selection for bexarotene therapy based on the adverse effect profile, not to identify those who will respond from a therapeutic standpoint. To our knowledge, this is the largest multicenter study 4, 20, 21 c.*40C>G, and APOE c.388T>C and c.526C>T polymorphisms had nonsignificantly higher baseline triglyceride levels. However, after bexarotene treatment was introduced, we observed that carriers of at least 1 of the minor alleles of APOA5 c.-1131T>C and APOC3 c.*40C>G showed a significantly less severe increase in triglyceride concentration. In contrast, APOA5 c.56G>C and the 2 APOE variants studied seemed to have no particular association with triglyceride concentrations during bexarotene therapy. These results are in apparent contradiction to previous knowledge on the biological effects of such conferring a higher risk for coronary artery disease, stroke, and metabolic syndrome. 24 A complete explanation for our results is difficult to establish, but a different hypothesis could be considered. Kim et al 25 showed that the APOA5 c.-1131T>C minor allele may lead to reduced ApoA-V concentration, with concomitantly reduced lipoprotein lipase activity, resulting in higher triglyceride levels in the general population. Those authors also observed that this association was reversed when triglyceride concentrations were greater than 150 mg/dL. We believe that a similar phenomenon may partially explain our results. However, we must acknowledge limitations for this hypothesis, because we did not specifically include ApoA-V concentrations in our work and the implications of these observations in the other apolipoprotein genotypes are unknown thus far. Another possible explanation for our results could be related to the association of some APO polymorphisms with the response to fenofibrate therapy. The recent Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study tested the association between the APOA1/C3/A4/A5 gene cluster and the lipid response to 3-week fenofibrate treatment. 26 In that study, the authors observed that the minor alleles of APOA5_S19W (c.56G>C), APOA4_N147S (c.440G>A), APOC3_G34G (c.102T>C), and APOC3_3U386 (c.*40G>C) were significantly associated with an enhanced triglyceride response to fenofibrate treatment. In addition, in another branch of the GOLDN study, the association between tagged single-nucleotide polymorphisms (c.-1131T>C and c.56G>C) at APOA5 and triglyceride and high-density lipoprotein cholesterol response to 3 weeks of fenofibrate treatment was examined in a group of 791 participants. In that study, it was observed that the minor allele carriers of the polymorphism c.56G>C presented a greater triglyceride level decrease and high-density lipoprotein cholesterol level increase in response to fenofibrate treatment compared with noncarriers. 27, 28 In another recent study (B.
Candás, doctoral thesis, Barcelona University, December 1, 2011) the APOA5 c.-1131T>C, APOA5 c.56G>C, APOC3 c*40C>G, and APOE c.388T>C polymorphisms and their association with fenofibrate response were investigated. In that work, carriers of the c*40C>G of the APOC3 gene responded to fenofibrate treatment up to 11% better than noncarriers. Because our patients were simultaneously treated with bexarotene and fenofibrate, these observations are in agreement with our data. We do not know the exact association of each polymorphism with fenofibrate therapy response; further pharmacogenomic studies are needed to address this question. In addition to the genetic results, laboratory data obtained in this study showed that a higher baseline triglyceride concentration was associated with higher maximal triglyceride concentrations during bexarotene treatment regardless of genetic polymorphisms. This association, not previously reported, could help physicians assess which patients will experience more severe hypertriglyceridemia. Our results also show that bexarotene is an effective treatment for CTCL, with a high overall response rate (84.5%). These data support the use of bexarotene for patients with refractory and advanced-stage CTCL. The response rate in our patients seems higher than would be expected based on previous reports. 4, 20, 21 We believe the greater response rate could be because almost 60% of our patients were in an early phase of the disease (stage I), in whom the response rate to bexarotene treatment is reported to be higher than for those in more advanced stages, including tumoral or erythrodermic phases. In a recent study, a Phase 3 Trial of Brentuximab Vedotin (SGN-35) vs Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA), 29 the results of that clinical trial comparing brentuximab vedotin with physician's choice (bexarotene or methotrexate) in CD30-positive CTCLs showed that overall response rate lasting 4 months in the physician's choice branch was 16%. We believe that, again, these differences in response could reflect that the number of patients with earlystage disease in ALCANZA was lower than that of patients in our series. In addition, all patients in the ALCANZA trial had CD30-positive mycosis fungoides. Because there is no information about earlier particular sensitivity to bexarotene in this setting, we believe it is difficult to contrast the ALCANZA results with standard cases of mycosis fungoides in regular clinical practice.
Limitations
The findings of the present study may help physicians assess which patients will have a better lipid-profile response and, consequently, which may have a bad outcome. However, the sensitivity of these polymorphisms for anticipating bad outcomes is not yet clear, and we cannot establish which patients will need to discontinue treatment or which will experience pancreatitis. More studies should be done to investigate these questions.
Conclusions
Cutaneous T-cell lymphoma is a rare disease with a reported annual incidence of about 6.4 to 9.6 cases per million people in the United States. 6 To our knowledge, this is the largest multicenter study to date evaluating patients with CTCL treated with bexarotene and the first to focus on the role of genetic polymorphisms in bexarotene-induced hypertriglyceridemia. Our results show that patients carrying at least 1 of the minor alleles of APOA5 c.-1131T>C or APOC3 c.*40C>G are less likely to experience severe hypertriglyceridemia. These data suggest that APO polymorphism investigation could be helpful in the clinical evaluation of bexarotene-induced hypertriglyceridemia in patients with CTCL and in the identification of the most suitable candidates for this therapy. 
